Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT05945732
DESTINY Breast Respond HER2-(Ultra)Low Europe
2,295 Enrollment(s)
216 Study location(s)
OBSERVATIONAL (None)
Unresectable Breast Cancer


Metastatic Breast Cancer


HER2-low Expressing Breast Cancer


HER2-(Ultra)Low Expressing Breast Cancer
RECRUITING
NCT06846996
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
260 Enrollment(s)
40 Study location(s)
OBSERVATIONAL (None)
HER2-positive Gastric Cancer


HER2-positive Gastroesophageal Junction
RECRUITING
NCT06809764
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
150 Enrollment(s)
36 Study location(s)
OBSERVATIONAL (None)
Non-small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
NCT05246514
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
72 Enrollment(s)
28 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-mutant Non-Small Cell Lung Cancer
RECRUITING
NCT07069712
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
100 Enrollment(s)
70 Study location(s)
INTERVENTIONAL (PHASE2)
Gastroesophageal Adenocarcinoma
RECRUITING
NCT05408845
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
146 Enrollment(s)
152 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Salivary Gland Carcinoma


Recurrent Salivary Gland Carcinoma


Stage III Major Salivary Gland Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Unresectable Salivary Gland Carcinoma
RECRUITING
NCT07543536
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
132 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE3)
Advanced/Metastatic Breast Cancer


HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
RECRUITING
NCT05417594
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
695 Enrollment(s)
32 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Solid Malignancies